MIAMI, FL, Feb. 11, 2016 – Jeffrey Zucker, vice president of Feasibility and Recruitment Optimization at Worldwide Clinical Trials, will present at this year’s Summit for Clinical Operations Executives (SCOPE), being held Feb. 23-25 at the Hyatt Regency in Miami, FL. Zucker will discuss how sponsors can rebuild and enhance site partnerships to optimize study execution, supporting SCOPE’s ”Improving Site Study Activation and Performance” portion of the conference. His presentation will take place on Thursday, Feb. 25 at 11:05 a.m.

In addition to Zucker’s presentation, experts from the Worldwide Clinical Trials team will also be on-hand at the company’s booth (#311) to discuss the individual drug development challenges of SCOPE attendees, as well as their concerns and needs across a range of therapeutic areas, including neuroscience, cardiovascular disease, inflammatory disorders, and rare disease.

“The strategic balance of science, medicine and operations provides the foundation for successful execution of clinical trials,” explains Zucker, who has more than 20 years of experience in clinical research operations. “While there are many challenges in trial planning and execution, during my presentation at SCOPE, I will explore how the relationship between the sponsor and the clinical trial site can have a significant impact on the efficiency and overall success of a clinical trial. From trial start-up and recruitment through implementation, I will offer strategies for establishing and maintaining key relationships, while defining the impact of a strong partnership.”

The seventh annual SCOPE Summit will offer three days of discussions, conferences and workshops covering all aspects of clinical trial planning and management. To schedule an appointment with a Worldwide expert at SCOPE, visit www.worldwide.com/events. For further information about SCOPE, visit www.scopesummit.com.

About Worldwide Clinical Trials
Worldwide Clinical Trials provides full-service drug development services to the pharmaceutical and biotechnology industries from Early Phase and Bioanalytical Sciences through Phase II and III trials to Peri-Approval studies. We believe successful drug development strategically balances science, medicine, operations and commercial intelligence. We approach every Phase I-IV drug development program as unique. Our mission is to foster the development of life changing medicines by integrating innovative methodology, rigorous science and efficient technology. For more information, visit www.Worldwide.com.

MEDIA CONTACT:
LuJean Smith, VP of Marketing Communications, lujean.smith@worldwide.com, USA: 610.964.2002